Michael J. Haller, M.D., MS-CI

Michael HallerDivision


Academic Title

Associate Professor

Contact Information

352-273-9264 (phone)
352-273-9396 (fax)


Biomedical Sciences Building, J-591

Research Overview

Type 1 diabetes is an autoimmune disease characterized by the T cell mediated destruction of insulin producing beta cells resulting in a life-long dependence on multiple daily insulin injections to avoid the long term complications of diabetes. Type 1 diabetes affects nearly 1 in every 300 people in the United States and the incidence is on the rise. Dr. Haller’s research focuses on predicting, preventing, and reversing type 1 diabetes through a team approach that focuses on translating finding from the laboratory bench to the patient’s bedside in a timely manner.

Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet and The Environmental Determinants of Diabetes in Youth (TEDDY) study. Dr. Haller s the PI of promising studies seeking to utilize combination therapies with antithyrmocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in patients with both recent onset and established type 1 diabetes 1 diabetes. In addition, Dr. Haller served as the PI of a “first in man” study aimed at using autologous umbilical cord blood stem cells as a potential therapy for type 1 diabetes.

In 2008, Dr. Haller, and his colleagues Dr. Desmond Schatz and Dr. Mark Atkinson received the JDRF’s highest award, the Mary Tyler Moore and S.Robert Levine Excellence in Clinical Research Award, for their team approach to developing therapies for type 1 diabetes.. In addition, Dr. Haller has received the Lawson Wilkins Clinical Scholar award, a JDRF innovative research award, a JDRF Early Career Clinically Oriented, and the ISPAD Young investigator award. Dr. Haller is currently funded by the NIH, the JDRF, and The Helmsley Trust to support his work in developing combination therapies for Type 1 diabetes.


Dr. Haller is currently an Associate Professor of Pediatrics at the University of Florida. After completing his undergraduate education at Duke University, Dr. Haller returned to his birthplace of Gainesville, Florida where he completed medical school, residency training in pediatrics, and fellowship training in pediatric endocrinology. Dr. Haller first began working in Type 1 diabetes research during his first year of medical school and has since committed his academic career to developing safe and effective therapies for the prevention and reversal of Type 1 diabetes. Dr. Haller has published over 75 manuscripts and book chapters relating to type 1 diabetes.

Key Publications

Additional publications can be found in PubMed.

  1. Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease.
    Elding Larsson H, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, Lernmark Å, Rewers M, Simell O, She JX, Ziegler A, Haller MJ; TEDDY Study Group. Pediatr Diabetes. 2014
    Mar;15(2):118-26. doi: 10.1111/pedi.12066. Epub 2013 Aug 27.
  2. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis.
    Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ; Pediatric Diabetes Consortium.
    Pediatr Diabetes. 2014 Jun;15(4):287-93. doi: 10.1111/pedi.12068. Epub 2013 Aug 15.
  3. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.
    Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA.
    Biol Blood Marrow Transplant. 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20
  4. Type 1 diabetes: current concepts in epidemiology, pathophysiology, clinical care, and research.
    Gan MJ, Albanese-O’Neill A, Haller MJ.
    Curr Probl Pediatr Adolesc Health Care. 2012 Nov-Dec;42(10):269-91. doi: 10.1016/j.cppeds.2012.07.002. Review.
  5. Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
    Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA.
    Diabetes. 2009 Oct;58(10):2277-84. doi: 10.2337/db09-0557. Epub 2009 Jul 23.